Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis.
Georgia TrakadaDespina FotiouAnastasios KallianosFoteini TheodorakakouMagdalini MigkouMaria GavriatopoulouNikolaos KanelliasPanagiotis MalandrakisIoannis Ntanasis-StathopoulosEvangelos Eleutherakis-PapaiakovouIoanna DialoupiEvangelos TerposMeletios- Athanasios DimopoulosEfstathios KastritisPublished in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2022)
Pulmonary dysfunction, as assessed with PFTs, is common and underrecognized in patients with systemic AL amyloidosis, with significant prognostic and potentially therapeutic implications, independent of the degree of cardiac dysfunction or chest-CT findings.